108 related articles for article (PubMed ID: 2749585)
1. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients.
van Geet C; Hauglustaine D; Verresen L; Vanrusselt M; Vermylen J
Thromb Haemost; 1989 Feb; 61(1):117-21. PubMed ID: 2749585
[TBL] [Abstract][Full Text] [Related]
2. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
[TBL] [Abstract][Full Text] [Related]
3. Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis.
Fabris F; Cordiano I; Randi ML; Casonato A; Montini G; Zacchello G; Girolami A
Pediatr Nephrol; 1991 Mar; 5(2):225-8. PubMed ID: 2031840
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of platelet function during treatment with recombinant human erythropoietin (r-HuEPO) in patients hemodialyzed and dialyzed peritoneally].
Janicka L; Majdan M; Dmoszyńska A; Ksiazek A; Berger B; Baranowska E
Wiad Lek; 1993 Oct; 46(19-20):756-60. PubMed ID: 7975620
[TBL] [Abstract][Full Text] [Related]
5. Expression of fibrinogen receptors and GPIIb molecules on uraemic platelets: effect of recombinant human erythropoietin therapy.
Krzesłowska J; Rysz J; Cierniewski CS; Luciak M
Nephrol Dial Transplant; 1995; 10(5):653-6. PubMed ID: 7566578
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients.
el-Shahawy MA; Francis R; Akmal M; Massry SG
Clin Nephrol; 1994 May; 41(5):308-13. PubMed ID: 8050212
[TBL] [Abstract][Full Text] [Related]
7. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620
[TBL] [Abstract][Full Text] [Related]
8. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.
Maurin N; Fitzner S; Fritz H; Gladziwa U; H agel J; Stefanidis I
Clin Nephrol; 1995 Mar; 43(3):196-200. PubMed ID: 7774078
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin therapy in haemodialysis patients--dose determination and clinical experience.
Bommer J; Alexiou C; Müller-Bühl U; Eifert J; Ritz E
Nephrol Dial Transplant; 1987; 2(4):238-42. PubMed ID: 3118264
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of platelet hemostasis in patients with chronic renal failure].
Krawczyk W; Dmoszyńska A; Sokołowska B
Wiad Lek; 1994 Feb; 47(3-4):93-9. PubMed ID: 7975649
[TBL] [Abstract][Full Text] [Related]
11. Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients.
Roger SD; Piper J; Tucker B; Raine AE; Baker LR; Kovacs IB
Nephrol Dial Transplant; 1993; 8(3):213-7. PubMed ID: 8385286
[TBL] [Abstract][Full Text] [Related]
12. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
Boran M; Dalva I; Yazicioğlu A; Akbay E; Cetin S
Int Urol Nephrol; 1993; 25(2):197-203. PubMed ID: 8365853
[TBL] [Abstract][Full Text] [Related]
13. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
[TBL] [Abstract][Full Text] [Related]
14. [Extrinsic coagulation pathway in peritoneally dialyzed patients treated with erythropoietin].
Małyszko J; Małyszko JS; Suchowierska E; Pawlak K; Myśliwiec M
Przegl Lek; 2002; 59(3):139-41. PubMed ID: 12184025
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilisation in uraemic children: a possible link?
Van Geet C; Van Damme-Lombaerts R; Vanrusselt M; de Mol A; Proesmans W; Vermylen J
Thromb Haemost; 1990 Aug; 64(1):7-10. PubMed ID: 2274929
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation.
Gordge MP; Leaker B; Patel A; Oviasu E; Cameron JS; Neild GH
Thromb Res; 1990 Jan; 57(2):171-82. PubMed ID: 2315882
[TBL] [Abstract][Full Text] [Related]
17. Vital indication for erythropoietin in a chronic haemodialysis patient. A case report.
Nielsen OJ; Thaysen JH
Dan Med Bull; 1989 Dec; 36(6):590-2. PubMed ID: 2612227
[TBL] [Abstract][Full Text] [Related]
18. The effect of tranexamic acid on bleeding time and haemostasis.
Menzies SA; Hartley JA; Hitchcock ER; Rorke E; Gill JS
Neurochirurgia (Stuttg); 1991 Sep; 34(5):141-3. PubMed ID: 1745318
[TBL] [Abstract][Full Text] [Related]
19. [Effects of the treatment with human recombinant erythropoietin on primary hemostasis in uremic patients].
Cases A; Escolar G; Reverter JC; Garrido M; Ordinas A; López-Pedret J; Castillo R; Revert L
Med Clin (Barc); 1990 Nov; 95(17):644-7. PubMed ID: 2089202
[TBL] [Abstract][Full Text] [Related]
20. Improvement of bleeding time, platelet aggregation and platelet count during CAPD treatment.
Arends JP; Krediet RT; Boeschoten EW; van der Lelie J; Veenhof CH; von dem Borne AE
Proc Eur Dial Transplant Assoc; 1981; 18():280-5. PubMed ID: 7329972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
